Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety and population PK of HMS5552 add-on to Metformin
in adult type 2 diabetic subjects. There will be 2 groups in the first 24 weeks, one group
will receive HMS5552 plus Metformin, while the other group will receive placebo plus
Metformin; after 24 weeks, all subjects will receive HMS5552 plus Metformin for 28 weeks.